Noben (idebenone) at a dose of 120 mg per day for six months was used in the treatment of 35 patients aged 60–86 years with Alzheimer’s-type dementia, mixed dementia, and memory impairments not reaching the stage of dementia. Patients were assessed on the basis of data from somatic, neurological, and psychiatric investigations, as well as neuropsychological testing and a series of psychometric and other scales and tests, before and after treatment. Significant improvements in patients’ conditions on the MMSE were seen in patients with mild and moderate dementia. Improvements in daily activities were obtained in 27% of patients. Neuropsychological investigations demonstrated improvements in short-term and long-term memory and attention, with improvements in speech functions, performance of kinesthetic, spatial, and dynamic praxis tests, and in visuospatial gnosis, thought, and writing. On the CGI scale, positive treatment effects were obtained in 37% of patients, while 48% of patients remained in a stable state.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
S. I. Gavrilov and G. A. Zharikov, “Galantamine (reminil) in the treatment of Alzheimer’s disease and vascular dementia,” Zh. Nevrol. Psikhiatr., 12, 59–65 (2003).
S. I. Gavrilov, “Alzheimer’s disease: diagnosis and treatment,” Vrach, 6, 1–4 (2004).
S. N. Illarioshkin et al., Inherited Ataxias and Paraplegias [in Russian], Medpress-Inform, Moscow (2006), p. 415.
V. N. Krasnov, A. P. Myzychenko, et al., “The new neurometabolic cerebroprotector idebenone: potential for use in psychiatry,” Sots. Klin. Psikhiatr., 1, 61–63 (2000).
R. Artuch, et al., “Friedreich’s ataxia: idebenone treatment in early stage patients,” Neuropediatrics, 33, No. 4, 190–193 (2002).
B. Bergamasco, et al., “Effects of idebenone in elderly subjects with cognitive decline. Results of a multicentre clinical trial,” Arch. Gerontol. Geriatr., 15, No. 3, 279–286 (1992).
B. Bergamasco, et al., “Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type,” Funct. Neurobiol., 9, No. 3, 161–168 (1994).
G. Buyse et al., “Idebenone treatment in Friedreich’s ataxia: neurological, cardiac, and biochemical monitoring,” Neurobiology, 60, 1679–1681 (2003).
T. Erkinjuntti, G. Roman, and S. Gauthier, “Treatment of vascular dementia evidence from clinical trials with cholinesterase inhibitors,” J. Neurol. Sci., 226, No. 1–2, 63–66 (2004).
J. G. Evans, G. Wilcock, and J. Birks, “Evidence-based pharmacotherapy of Alzheimer’s disease,” Int. J. Neuropsychopharmacol., 7, No. 3, 351–369 (2004).
V. Geromel, N. Darin, D. Chretien, et al., “Coenzyme Q and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits,” Molec. Genet. Metab., 77, 21–30 (2002).
H. Gutzmann et al., “Safety and efficacy of idebenone versus tacrine in patients with Alzheimer’s disease: results of a randomized, double-blind, parallel-group multicenter study,” Pharmacopsychiatry, 35, 12–18 (2002).
N. L. Keltner, A. L. Zielinski, and M. S. Hardin, “Drugs used for cognitive symptoms of Alzheimer’s disease,” Perspect. Psychiatr. Care, 37, No. 1, 31–34 (2001).
D. H. McDaniel et al., “Idebenone: a new antioxidant – Part I. Relative assessment of oxidative stress protection capacity compared to commonly known antioxidants,” J. Cosm. Dermatol., 4, No. 1, 10–17 (2005).
A. Merdente, G. Martorana, G. Minotti, and B. Giardina, “Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone),” Chem. Res. Toxicol., 11, No. 1, 54–63 (1998).
T. Nabeshima, A. Nitta, K. Fuji, et al., “Oral administration of NGF synthesis stimulators recovers reduced brain NGF content in aged rats and cognitive dysfunction in basal-forebrain-lesioned rats,” Gerontology (Basel), 40, Suppl. 2, 46–56 (1994).
A. Napolitano, “Long-term treatment with idebenone and riboflavin in a patient with MELAS,” Neurol. Sci., 21, No. 5, Suppl., S981–S982 (2000).
G. Nappi, “Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly,” Arch. Gerontol. Geriatr., 15, No. 3, 261–269 (1992).
C. Scavini, A. Rozza, E. Lanza, et al., “Effect of idebenone on in vivo serotonin release and serotonergic receptors in young and aged rats,” Eur. Neuropsychopharmacol., 6, 95–102 (1996).
I. Schols et al., “Therapeutic strategies in Friedreich’s ataxia,” J. Neurol. Transm., 68, Suppl., 135–145 (2004).
U. Senin, “Idebenone in senile dementia of Alzheimer type: a multi-centre study,” Arch. Gerontol. Geriatr., 15, No. 3, 249–260 (1992).
Y. Sugiyama and T. Fujita, “Stimulation of respiratory and phosphorylating activities in rat brain mitochondria by idebenone (CV-2619), a new agent improving cerebral metabolism,” FEBS Lett., 184, 48–51 (1985).
L. J. Thai et al., “Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease,” Neurology, 61, No. 11, 1498–1502 (2003).
K. Yanagisawa “Natural progression of Alzheimer’s disease (AD): a perspective on possible therapies for advanced AD,” Rinsho Shinkeigaku, 44, No. 11, 921–923 (2004).
Author information
Authors and Affiliations
Additional information
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 108, No. 4, pp. 27–32, April, 2008.
Rights and permissions
About this article
Cite this article
Voronkova, K.V., Meleshkov, M.N. Use of Noben (idebenone) in the Treatment of Dementia and Memory Impairments without Dementia. Neurosci Behav Physi 39, 501–506 (2009). https://doi.org/10.1007/s11055-009-9148-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-009-9148-0